Valuation: Cumberland Pharmaceuticals Inc.

Market Cap 74.17M 66.51M 61.39M 55.67M 104M 7.06B 105M 734M 292M 3.69B 278M 272M 11.7B P/E 2024
-5.14x
P/E 2025 -20.8x
Enterprise Value 72.9M 65.37M 60.35M 54.72M 102M 6.94B 103M 721M 287M 3.63B 273M 268M 11.5B EV / Sales 2024
0.95x
EV / Sales 2025 1.31x
Free-Float
57.75%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Cumberland Pharmaceuticals Inc.

1 day-1.62%
1 week-38.82%
Current month-37.80%
1 month-36.01%
3 months-30.73%
6 months+16.23%
Current year+22.36%
1 week 4.2
Extreme 4.2001
8.76
1 month 4.2
Extreme 4.2001
8.76
Current year 2.69
Extreme 2.69
9.28
1 year 1.85
Extreme 1.85
9.28
3 years 1.04
Extreme 1.04
9.28
5 years 1.04
Extreme 1.04
9.28
10 years 0
Extreme 0
9.28
Manager TitleAgeSince
Chief Executive Officer 67 07/01/1999
Director of Finance/CFO 70 17/05/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 07/01/1999
Director/Board Member 74 10/09/2010
Director/Board Member 78 01/01/2010
Date Insider Type Main position Quantity % Market Cap. Importance
18/03/26 Free

Executive/Senior Manager

3,000 0.0201%
18/03/26 Free

Director

5,800 0.0388%
18/03/26 Free

Director

1,800 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-38.82% - - 74.17M
Average -1.62%
Weighted average by Cap. -1.62%

Financials

2024 2025
Net sales 37.87M 33.96M 31.35M 28.43M 52.97M 3.61B 53.71M 375M 149M 1.89B 142M 139M 5.98B 44.52M 39.92M 36.85M 33.42M 62.28M 4.24B 63.15M 441M 176M 2.22B 167M 164M 7.02B
Net income -6.48M -5.81M -5.36M -4.86M -9.06M -617M -9.19M -64.11M -25.55M -323M -24.31M -23.8M -1.02B -2.84M -2.54M -2.35M -2.13M -3.97M -270M -4.02M -28.06M -11.18M -141M -10.64M -10.42M -448M
Net Debt 2.61M 2.34M 2.16M 1.96M 3.65M 248M 3.7M 25.81M 10.28M 130M 9.78M 9.58M 412M -1.26M -1.13M -1.05M -949K -1.77M -120M -1.79M -12.51M -4.98M -62.98M -4.74M -4.64M -199M
Projected Income Statement - Annual - Cumberland Pharmaceuticals Inc.
Logo Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions. Its product candidates include Dyscorban (ifetroban), Vasculan (ifetroban) and Fibroban. Dyscorban (ifetroban) oral capsule is being developed for the treatment of the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Vasculan (ifetroban) oral capsule has been developed for the treatment of systemic sclerosis (SSc), also known as scleroderma. It is a rare autoimmune disorder that results in a thickening of the skin and internal organs. Fibroban oral capsule is developed for the treatment of idiopathic pulmonary fibrosis (IPF). Its commercial products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Acetadote (acetylcysteine) injection has been developed for the treatment of acetaminophen poisoning. Caldolor (ibuprofen) injection is developed for the treatment of pain and fever.
Employees
88
Date Price Change Volume
28/10/26 $4.870 -1.62% 141,175
27/10/26 $4.950 +13.79% 542,992
26/10/26 $4.350 -48.76% 501,543
23/10/26 $8.490 +0.12% 44,315
22/10/26 $8.480 +3.79% 39,177
  1. Stock Market
  2. Stocks
  3. CPIX Stock